The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor ... one for peptide synthesis and ...

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing ... which is consistent with maximum stimulation of muscle protein synthesis. Patients can also aim to consume protein three ...

such as glucagon-like peptide-1, free fatty acids, and catecholamines. With this knowledge, scientists are seeking to better understand the role of GPCRs in islet biology and hormone secretion ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...